AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

11,042.00p
   
  • Change Today:
    -164.00p
  • 52 Week High: 13,276.00
  • 52 Week Low: 9,501.00
  • Currency: UK Pounds
  • Shares Issued: 1,550.29m
  • Volume: 2,329,887
  • Market Cap: £171,184m
  • RiskGrade: 123

AstraZeneca, Daiichi's Enhurtu gets US approval to treat lung cancer

By Frank Prenesti

Date: Friday 12 Aug 2022

LONDON (ShareCast) - (Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu drug has been approved in the US for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer, the companies said on Friday.
They added that the approval applied to patients whose tumours have activating HER2 mutations, as detected by a Food and Drug Administration -approved test, and who have received a prior systemic therapy.

"This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial," the companies said in a statement.

Reporting by Frank Prenesti at Sharecast.com

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 11,042.00p
Change Today -164.00p
% Change -1.46 %
52 Week High 13,276.00
52 Week Low 9,501.00
Volume 2,329,887
Shares Issued 1,550.29m
Market Cap £171,184m
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
92.03% below the market average92.03% below the market average92.03% below the market average92.03% below the market average92.03% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Price Trend
6.17% above the market average6.17% above the market average6.17% above the market average6.17% above the market average6.17% above the market average
52.00% above the sector average52.00% above the sector average52.00% above the sector average52.00% above the sector average52.00% above the sector average
Income
88.49% below the market average88.49% below the market average88.49% below the market average88.49% below the market average88.49% below the market average
33.33% below the sector average33.33% below the sector average33.33% below the sector average33.33% below the sector average33.33% below the sector average
Growth
88.65% above the market average88.65% above the market average88.65% above the market average88.65% above the market average88.65% above the market average
94.12% above the sector average94.12% above the sector average94.12% above the sector average94.12% above the sector average94.12% above the sector average

What The Brokers Say

Strong Buy 9
Buy 15
Neutral 5
Sell 0
Strong Sell 1
Total 30
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  1st Interim 2nd Interim
Ex-Div 08-Aug-24 22-Feb-24
Paid 09-Sep-24 25-Mar-24
Amount 100.00¢ 197.00¢

Trades for 31-Oct-2024

Time Volume / Share Price
16:09 179,211 @ 11,160.00p
16:51 488 @ 11,042.00p
16:51 142 @ 11,042.00p
16:35 3,725 @ 11,042.00p
16:35 75 @ 11,042.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page